Monthly Prescribing Reference

Fixed-Dose Combo Mydcombi Ophthalmic Spray Approved to Induce Mydriasis

Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...
Mena FN

Mydriasis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies And Companies By Delveinsight

"Mydriasis Treatment Market"Mydriasis Companies are Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others (Albany, USA) DelveInsight's ...
Nature

Mydriasis after the treatment of vindesine in a patient with acute promyelocytic leukemia

Vindesine (VDS), one of the vinca alkaloids, is widely used as an antineoplastic agent. Possible target sites are microtubules and tubulins in cancer cells. As the adverse effects of VDS, ...
Monthly Prescribing Reference

Ryzumvi Approved for Reversal of Pharmacologically-Induced Mydriasis

Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...
Healio

FDA approves Ryzumvi for treatment of pharmacologically induced mydriasis

Please provide your email address to receive an email when new articles are posted on . The FDA approved Ryzumvi for the treatment of pharmacologically induced mydriasis. Ryzumvi is expected to be ...
Healio

Ryzumvi safely, rapidly reverses pharmacologically-induced mydriasis

Please provide your email address to receive an email when new articles are posted on . Significantly more participants treated with phentolamine ophthalmic solution 0.75% vs. placebo achieved ...
Yahoo Finance

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

FARMINGTON HILLS, Mich., May 20, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing ...
KOIN 6

RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024

FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and ...
Mena FN

Mydriasis Epidemiology, Symptoms, Prevalence and Diagnosed Population, and Treatment by Delveinsight

DelveInsight’s ‘Mydriasis Epidemiology Forecast 2030’ report delivers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, ...
MedPage Today

Mydriasis-Reversing Eye Drops Win FDA Approval

The FDA has approved phentolamine ophthalmic solution (Ryzumvi) 0.75% for treatment-induced mydriasis, Viatris and Ocuphire Pharma announced. The approval stipulates use of the eye drops to manage ...
Seeking Alpha

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis ...

FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and ...